Atrial Fibrillation Pipeline

DelveInsight’s Atrial Fibrillation pipeline report covers the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Key Facts from the Atrial Fibrillation Pipeline Report

• There are 5+ drugs in the Atrial Fibrillation pipeline.
• The Atrial Fibrillation pipeline consists of therapies in different clinical phase stages, including CKD-825, Botulinum toxin A, Gencaro, AGN-151607, HSY 244, HBI-3000, HIP-2001, VE 1902, CTP-Amio, ESP-001, and others.
• Leading players actively working to improve the Achondroplasia treatment landscape are Chong Kun Dang Pharmaceutical, Merz Pharma, ARCA biopharma, AbbVie, Novartis, HUYA Bioscience, Hanmi Pharmaceutical, Verseon, Vivasc Therapeutics, Espero BioPharma, and others.
• The Atrial Fibrillation therapies in the late stage of development include CKD-825 (Chong Kun Dang Pharmaceutical), Botulinum toxin A (Merz Pharma), and others.
• ESP-001 is being developed and investigated in the early stage of development by Espero BioPharma.

Get a detailed analysis of the pipeline landscape @ Atrial Fibrillation Pipeline Outlook

Atrial Fibrillation Overview

Atrial Fibrillation is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure, and other heart complications. During atrial fibrillation, the heart’s two upper chambers (the atria) beat chaotically and irregularly, out of sync with the two lower chambers (the ventricles).

Atrial Fibrillation Symptoms

Some people with atrial fibrillation have no symptoms and are unaware of their condition until a physical examination reveals it. Those who have atrial fibrillation symptoms may experience the following signs and symptoms: palpitations, which are sensations of a racing, uncomfortable, irregular heartbeat or a flip-flopping in your chest, weakness, decreased ability to exercise, Fatigue, lightheadedness, dizziness, shortness of breath, and chest pain are all symptoms of a heart condition.

Atrial Fibrillation Treatment

In hemodynamically unstable patients, immediate evaluation and treatment, including emergency cardioversion if necessary, are required. Treatment in stable patients is determined by the duration of atrial fibrillation and, during atrial fibrillation, the presence of underlying cardiac disease or other comorbidities. The treatment of AF presents three major therapeutic quandaries.

Atrial Fibrillation Pipeline Analysis: Drug Profiles

Gencaro: ARCA biopharma

Product Description

Gencaro (bucindolol hydrochloride) is a pharmacologically specific beta-blocker and mild vasodilator in a clinical trial to treat and prevent recurrent atrial fibrillation, or AF, in patients with heart failure with mid-range ejection fraction, or HFmrEF. 

Phase II

NCT01970501: ARCA Biopharma launched the “GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure” trial in April 2014.

Atrial Fibrillation Pipeline Therapies and Key Companies

• CKD-825: Chong Kun Dang Pharmaceutical 
• Botulinum toxin A: Merz Pharma
• Gencaro: ARCA biopharma
• AGN-151607: AbbVie
• HSY 244: Novartis
• HBI-3000: HUYA Bioscience
• HIP-2001: Hanmi Pharmaceutical
• VE 1902: Verseon
• CTP-Amio: Vivasc Therapeutics
• ESP-001: Espero BioPharm

Find out the emerging therapies and companies @ Atrial Fibrillation Clinical Trials

Atrial Fibrillation Therapeutics Assessment

• By Product Type
• Monotherapy
• Combination Therapy
• By Stage
• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
• By Route of Administration
• Inhalation
• Intravenous
• Oral
• Subcutaneous
• By Molecule Type
• Small Molecule
• Stem Cell Therapy
• Gene Therapy
• Targets
• Immune System
• Multiple Kinase
• By Mechanism of Action
• Protease Inhibitors
• Immunomodulatory

Scope of the Report

Coverage: Global

Atrial Fibrillation Key Players: Chong Kun Dang Pharmaceutical, Merz Pharma, ARCA biopharma, AbbVie, Novartis, HUYA Bioscience, Hanmi Pharmaceutical, Verseon, Vivasc Therapeutics, Espero BioPharma, among others

Atrial Fibrillation Pipeline Therapies: CKD-825, Botulinum toxin A, Gencaro, AGN-151607, HSY 244, HBI-3000, HIP-2001, VE 1902, CTP-Amio, ESP-001, and others

Table of Contents

Get in touch with our business executive for Healthcare Due Diligence Services

Key questions answered in the Atrial Fibrillation Pipeline Report

• What are the treatment options for Atrial Fibrillation?
• How many pharmaceutical companies are working on Atrial Fibrillation treatments?
• Which of these firms’ pharmaceuticals is the most widely used?
• How many companies produce atrial Fibrillation medications?
• How many drugs aimed at Atrial Fibrillation are in the early, middle, or late stages of development?
• How many current therapies can be used alone or in combination with others?
• What are the most significant Atrial Fibrillation collaborations, mergers and acquisitions, and licensing strategies?

Related Reports

Atrial Flutter Market

DelveInsight’s “Atrial Flutter Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Atrial Flutter, historical and forecasted epidemiology, and the Atrial Flutter market trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/